当前位置: 首页 >> 检索结果
4364. Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study.
作者: G Michael Felker.;Rebecca North.;Hillary Mulder.;W Schuyler Jones.;Kevin J Anstrom.;Mahesh J Patel.;Javed Butler.;Justin A Ezekowitz.;Carolyn Lam.;Christopher M O'Connor.;Lothar Roessig.;Adrian F Hernandez.;Paul W Armstrong.; .
来源: Circulation. 2023年147卷8期694-696页 4369. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
作者: Truman J Milling.;Saskia Middeldorp.;Lizhen Xu.;Bruce Koch.;Andrew Demchuk.;John W Eikelboom.;Peter Verhamme.;Alexander T Cohen.;Jan Beyer-Westendorf.;C Michael Gibson.;Jose Lopez-Sendon.;Mark Crowther.;Ashkan Shoamanesh.;Michiel Coppens.;Jeannot Schmidt.;Pierre Albaladejo.;Stuart J Connolly.; .
来源: Circulation. 2023年147卷13期1026-1038页
Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of the final analyses are presented.
4370. Familial Associations of Complete Atrioventricular Block: A National Family Study in Sweden.
作者: Artur Fedorowski.;Per Rosengren.;Mirnabi Pirouzifard.;Jan Sundquist.;Kristina Sundquist.;Richard Sutton.;Bengt Zöller.
来源: Circ Genom Precis Med. 2023年16卷2期e003654页
Complete atrioventricular block (CAVB) is a major reason for implantation of permanent pacemakers, but knowledge of CAVB inheritance is sparse. This nationwide study aimed to determine the occurrence of CAVB in first-, second-, and third-degree relatives (full siblings, half-siblings, and cousins).
4372. Optimal Hemostatic Band Duration After Transradial Angiography or Intervention: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials.
作者: Muhammad Haisum Maqsood.;Samir Pancholy.;Kristin A Tuozzo.;Nicole Moskowitz.;Sunil V Rao.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2023年16卷2期e012781页
The optimal duration of hemostatic compression post transradial access is controversial. Longer duration increases the risk of radial artery occlusion (RAO) while shorter duration increases the risk of access site bleeding or hematoma. As such, a target of 2 hours is typically used. Whether a shorter or longer duration is better is not known.
4373. Sustained Mechanical Aspiration Thrombectomy for High Thrombus Burden Coronary Vessel Occlusion: The Multicenter CHEETAH Study.
作者: S Jay Mathews.;Sahil A Parikh.;Willis Wu.;D Christopher Metzger.;Jeffrey W Chambers.;Magdi G H Ghali.;Michael James Sumners.;Brian C Kolski.;Duane S Pinto.;Suhail Dohad.
来源: Circ Cardiovasc Interv. 2023年16卷2期e012433页
Poor myocardial reperfusion due to distal embolization and microvascular obstruction after percutaneous coronary intervention is associated with increased risk of morbidity and mortality. Prior trials have not shown a clear benefit of routine manual aspiration thrombectomy. Sustained mechanical aspiration may mitigate this risk and improve outcomes. The objective of this study is to evaluate sustained mechanical aspiration thrombectomy before percutaneous coronary intervention in high thrombus burden acute coronary syndrome patients.
4374. Contemporary Anatomic Criteria and Clinical Outcomes With Transcatheter Mitral Repair.
作者: Paul Sorajja.;Hirotomo Sato.;Vinayak N Bapat.;João L Cavalcante.;Richard Bae.;Miho Fukui.;Larissa Stanberry.;Maurice Enriquez-Sarano.
来源: Circ Cardiovasc Interv. 2023年16卷2期e012486页
Consensus-driven criteria have recently been proposed for prediction of mitral transcatheter edge-to-edge repair outcomes, yet validation for response to therapy is needed. We examined the relation between contemporary criteria and outcomes with mitral transcatheter edge-to-edge repair therapy.
4376. Multi-Omic Architecture of Obstructive Hypertrophic Cardiomyopathy.
作者: Ramin Garmany.;J Martijn Bos.;David J Tester.;John R Giudicessi.;Cristobal G Dos Remedios.;Surendra Dasari.;Nagaswaroop K Nagaraj.;Asha A Nair.;Kenneth L Johnson.;Zachary C Ryan.;Joseph J Maleszewski.;Steve R Ommen.;Joseph A Dearani.;Michael J Ackerman.
来源: Circ Genom Precis Med. 2023年16卷2期e003756页
Hypertrophic cardiomyopathy (HCM) is characterized by asymmetric left ventricular hypertrophy. Currently, hypertrophy pathways responsible for HCM have not been fully elucidated. Their identification could serve as a nidus for the generation of novel therapeutics aimed at halting disease development or progression. Herein, we performed a comprehensive multi-omic characterization of hypertrophy pathways in HCM.
4377. Continuous-Flow Intra-Aortic Percutaneous Mechanical Circulatory Support in Heart Failure With Worsening Renal Function.
作者: Gillian Grafton.;Cristina Tita.;Jason J Heuring.;Eric S Fain.;Palak Shah.;Jennifer A Cowger.;Mohammad Alqarqaz.;Mir B Basir.
来源: Circ Heart Fail. 2023年16卷3期e009842页 4378. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
作者: Hertzel C Gerstein.;Zhuoru Li.;Chinthanie Ramasundarahettige.;Seungjae Baek.;Kelley R H Branch.;Stefano Del Prato.;Carolyn S P Lam.;Renato D Lopes.;Richard Pratley.;Julio Rosenstock.;Naveed Sattar.
来源: Circulation. 2023年147卷13期1004-1013页
In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse cardiovascular events (MACE) in people with type 2 diabetes at high cardiovascular risk. Whether these benefits are dose related remains uncertain.
4380. Multiancestry Genome-Wide Association Study of Aortic Stenosis Identifies Multiple Novel Loci in the Million Veteran Program.
作者: Aeron M Small.;Gina M Peloso.;Jason Linefsky.;Jayashri Aragam.;Ashley Galloway.;Vidisha Tanukonda.;Lu-Chen Wang.;Zhi Yu.;Margaret Sunitha Selvaraj.;Eric H Farber-Eger.;Michael T Baker.;Shefali Setia-Verma.;Simon S K Lee.;Michael Preuss.;Marylyn D Ritchie.;Scott M Damrauer.;Daniel J Rader.;Quinn S Wells.;Ruth Loos.;Steven A Lubitz.;George Thanassoulis.;Kelly Cho.;Peter W F Wilson.; .;Pradeep Natarajan.;Christopher J O'Donnell.
来源: Circulation. 2023年147卷12期942-955页
Calcific aortic stenosis (CAS) is the most common valvular heart disease in older adults and has no effective preventive therapies. Genome-wide association studies (GWAS) can identify genes influencing disease and may help prioritize therapeutic targets for CAS.
|